Phase 2 Study Evaluating the Safety and Effectiveness of AHB-137 Injection in Adults With Chronic Hepatitis B and Low HBsAg Levels

What this Trial Is About

Researchers are studying the safety and effectiveness of AHB-137 injection in adults with chronic hepatitis B CHB who have low levels of hepatitis B surface antigen HBsAg. This Phase 2, open-label, multicenter study aims to evaluate how well AHB-137 works alongside or without nucleostide analogue NA therapy in this population. Participants receive AHB-137 injections, with some also receiving NA therapy while others do not. The study includes different parts where participants may be treated with AHB-137 combined with NA therapy or AHB-137 alone. Treatment and monitoring continue through multiple weeks, including assessments after stopping all CHB treatments. During the study, participants undergo various tests to measure viral markers such as HBsAg, HBV DNA, and other related indicators, along with quality of life questionnaires. Researchers track the presence of anti-drug antibodies, drug resistance, and treatment-emergent adverse events for up to 60 weeks, including a key evaluation at 24 weeks after stopping all CHB treatment to assess persistent viral suppression.

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)